Abstract
SUMMARY Medullary thyroid cancer accounts for less than 10% of all thyroid cancers. Aggressive metastatic forms of this disease however, are incurable and can cause significant symptoms including diarrhea and pain. Hereditary and some sporadic forms of the disease are characterized by a mutation of the proto-oncogene RET. This results in an abnormal growth factor receptor that, in turn, allows the malignant cells to survive and metastasize. New tyrosine kinase inhibitors have been shown to effectively target RET in vitro. One of the first of these agents, vandetanib, has been evaluated in international Phase II and III clinical trials. In 2011, vandetanib became the first agent approved by the US FDA for use in metastatic medullary thyroid cancer. This article examines the clinical use of this agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
